Table 1: Summary of studies comparing p53 positive group vs. p53 negative group in endometrial carcinomas.
Study | Number of Patients | Histology | Outcomes |
Fadare, et al. [7] |
50 |
Clear cell carcinomas |
- Recurrence 73% in p53 positive group (P < 0.008) - PFS 56 vs. 88 months (P < 0.01) - OS 63 vs. 83 months (P = 0.07) |
Garg, et al.[9] |
35 |
Endometrioid endometrial carcinomas |
- 3-year PFS 52% vs. 94% (P = 0.02) - 3-year DSS 54% vs. 100% (P < 0.003) |
Catasus, et al.[10] |
132 |
Endometrial carcinomas - (77%) endometrioid adenocarcinomas - (11%) non-endometrioid adenocarcinomas - (12%) mixed endometrioid adenocarcinomas-non-endometrioid |
- Kaplan-Meier Survival Analysis (P = 0.000) |
Huvila, et al. [11] |
306 |
Endometrioid endometrial carcinomas |
- A 30-fold risk of dying of disease in high-risk group compared |
Obata, et al. [12] |
154 |
Endometrioid endometrial carcinomas |
- Recurrence or Metastasis - Grade 1-2: 37.8% vs. 5.3% (P < 0.01) - PFS 61.1% vs. 21.9% (P < 0.01). |
PFS: Progression Free Survival; OS: Overall Survival; DSS: Disease-Specific Survival.